Zydus Cadila begins phase-2 trial of drug to cure anaemia in kidney patients

Zyani1, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), is being tested as a viable treatment for anaemia associated with chronic kidney disease (CKD)

0
369
Download PDF
New Delhi: Anaemia commonly arises in kidney disease patients, because the kidneys no longer produce sufficient amounts of erythropoietin, a hormone which stimulates red blood cell production. It is considered to be a major medical problem in both developed as well as developing nations.
In a new development in this direction, the Cadila Pharmaceuticals, also known as Zydus Cadila has announced commencement of a Phase-II trial investigating Zyani1, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), as a treatment for anaemia associated with chronic kidney disease (CKD).
In a statement issued in Ahmedabad by Mr Pankaj Patel, Chairman and Managing Director, Zydus Cadila mentioned, “Zyani1 is an oral small molecule designed to increase natural production of haemoglobin and RBCs in anaemic patients. It has been shown to improve iron mobilisation and has the potential to reduce or eliminate the need for iron supplementation.”
“We have observed desired pharmacokinetic and safety profile in addition to positive signals in biomarker responses in the two Phase-I trials conducted in Australia and India,” he said.
The company says that Zyani1 has the potential to bring about a paradigm shift in the management of patients with anaemia as it could provide an oral, safer alternative to currently available erythropoietin-stimulating agents (ESAs), which must be given via injections.
It is important to note that the global ESA market was estimated at $7 billion worldwide.

NO COMMENTS